Pharmaceutical Technology

APRIL 13, 2023

Takeda has announced that it will be pivoting away from its discovery and preclinical programmes in adeno-associated virus (AAV) gene therapies. Takeda’s announcement underlines the risk associated with gene therapy R&D at the preclinical stage and the fact that many current AAV programs are unlikely to reach late-stage trials.

Gene Therapy 243

Gene Therapy Marketing Gene In-Vivo 243

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

World of DTC Marketing

JANUARY 31, 2021

I always have pointed instances in which pharma puts Wall Street first and patients second. Here are some of her key points from the report: 1ne: In just 10 years, the number of large, international pharmaceutical companies decreased six-fold,from60 to only 10. In pharma R&D returns have declined to 1.8 percent from 2018.

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

XTalks

DECEMBER 20, 2023

CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason. Given its ability to precisely edit genes, there is tremendous promise for the revolutionary technology to offer cures for genetic disorders and to treat various diseases.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

The Pharma Data

NOVEMBER 10, 2020

This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing. By giving companies full control of their studies, they are able to significantly speed up timelines,” Tessier said. Photo courtesy of Mispro.

Marketing 52

Marketing In-Vivo Scientist Research 52